Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III

This article was originally published in The Gray Sheet

Executive Summary

Current and future surgical mesh devices for pelvic organ prolapse repair would require PMA submissions under a recommendation last week by FDA’s Obstetrics and Gynecology Devices panel.
Advertisement

Related Content

FDA Proposes PMAs For Pelvic Organ Prolapse Mesh Devices
J&J/Ethicon Begins Worldwide Withdrawal Of Vaginal Mesh Products
Surgical Mesh And Sling Devices Must Undergo Post-Market Studies
Need More Women For Device Trials? Create Better Consent Forms, FDA Says
Need More Women For Device Trials? Create Better Consent Forms, FDA Says
FDA Panel Calls For More Studies Of Mini-Slings For Urinary Incontinence
FDA Should Rethink Its Definition Of A High-Risk Device, Say Patient Advocates
Urinary Incontinence: Mesh Slings Come Under Fire
Transvaginal Mesh Devices Reassessed: FDA Panel Set For September
Transvaginal Mesh Devices Reassessed: FDA Panel Set For September

Topics

Advertisement
UsernamePublicRestriction

Register

MT030517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel